Boston Research Management Inc buys $3,466,601 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Boston Research Management Inc scooped up 845 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 51,594 shares of AbbVie Inc which is valued at $3,466,601.AbbVie Inc makes up approximately 2.03% of Boston Research Management Inc’s portfolio.

Other Hedge Funds, Including , Fdo Partners sold out all of its stake in ABBV during the most recent quarter. The investment firm sold 9,455 shares of ABBV which is valued $635,281.Forbes J M Co Llp boosted its stake in ABBV in the latest quarter, The investment management firm added 683 additional shares and now holds a total of 98,135 shares of AbbVie Inc which is valued at $6,529,903. AbbVie Inc makes up approx 1.75% of Forbes J M Co Llp’s portfolio.Whittier Trust Co reduced its stake in ABBV by selling 3,940 shares or 1.57% in the most recent quarter. The Hedge Fund company now holds 247,059 shares of ABBV which is valued at $16,362,718. AbbVie Inc makes up approx 0.70% of Whittier Trust Co’s portfolio.Vigilant Capital Management reduced its stake in ABBV by selling 3,305 shares or 2.31% in the most recent quarter. The Hedge Fund company now holds 139,875 shares of ABBV which is valued at $8,869,474. AbbVie Inc makes up approx 1.65% of Vigilant Capital Management’s portfolio.

AbbVie Inc opened for trading at $66.57 and hit $67.18 on the upside on Friday, eventually ending the session at $67.1, with a gain of 0.49% or 0.33 points. The heightened volatility saw the trading volume jump to 67,09,360 shares. Company has a market cap of $109,275 M.

On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.